News – Page 9 – Endpoints News

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

4 weeks ago

Lyell’s lymphoma data for recently acquired CAR-T receive lukewarm reception on Wall Street

4 weeks ago

Prothena moves forward with layoffs; Aldeyra resubmits dry eye drug to FDA

4 weeks ago

Mineralys gets a mid-stage win in hypertension patients with poor renal function

4 weeks ago

Dyne pivots on primary endpoint, delays filing for DM1 drug

4 weeks ago

Isomorphic to open US office in Cambridge, hires ex-Relay CMO

4 weeks ago

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

4 weeks ago

Immuneering says MEK pill beats standard of care in first-line pancreatic cancer

4 weeks ago

Fired vaccine advisors defend ACIP’s work, independence in joint editorial

4 weeks ago

Purdue opioid settlement gets backing from 55 attorneys general

4 weeks ago

Eli Lilly makes all Zepbound doses available in single-dose vials

4 weeks ago

What's coming in five years? FDA chief points to universal flu vaccine, new approval pathway

4 weeks ago

AbbVie’s cancer drug fails Phase 3 combo study to treat other bone marrow diseases

4 weeks ago

Roche moves ahead with Phase 3 Parkinson’s study despite mixed trial results

4 weeks ago

Incyte’s promising thrombocythemia drug; Crescent Biopharma raises $200M in PIPE

4 weeks ago

NextCure inks ADC deal with Shanghai drugmaker

4 weeks ago

Help us find 2025's best biotech startups: Nominations are open for Endpoints 11

4 weeks ago

Updated: Sage's roller coaster ends in $561M acquisition by Supernus

4 weeks ago

Lilly posts encouraging early-stage weight loss data on amylin candidate

4 weeks ago

Gilead, Arcellx continue to spotlight safety of multiple myeloma cell therapy

4 weeks ago

Sarepta halts Duchenne gene therapy in some patients after second death

4 weeks ago

RFK removes all ACIP members, names new ones; National Resilience to close six sites; Deals and financing recap of ...

4 weeks ago

Former CEO Anne Wojcicki wins bid for 23andMe

4 weeks ago

KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’

4 weeks ago

First page Previous page 6 7 8910 11 12 Next page Last page